Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Protectimmun Gets Positive Scientific Advice Response from EMA for Innovative Allergy Prophylaxis

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
Protectimmun GmbH has successfully discussed the overall clinical development plan for its innovative allergy prophylaxis against hay fever and allergic asthma.

The Agency agreed to the biological rationale of the allergy prevention concept and endorses the proposed key elements of the clinical safety and efficacy studies including study population, duration, and endpoints.

"We are very pleased to get this favourable opinion from EMA’s medical experts”, says Marion Kauth, CEO and co-founder of Protectimmun. "It is the reward for our efforts to elaborate the complete development plan for this first-in-class innovation at the earliest and to carefully consider the special issues for a preventive approach in children.”

Nose drops for the prevention of hay fever and asthma

Protectimmun is a pharmaceutical R&D company focussed on new approaches in the prevention and therapy of allergic and chronic inflammatory diseases. Its lead development is a first-in-class medicinal product that may offer long-lasting protection against the development of hay fever and allergic asthma in infants. The product contains probiotic bacteria from a specific farm environment and will be applied as nose drops. Application via the nasal mucosa mimics the natural exposure of farm children by intensive barn contact in early life that has been shown to be allergy-protective in large epidemiological studies. More than 5 million infants would be eligible for this preventive treatment in Europe and the USA each year.

Professor Albrecht Bufe, paediatrician and co-founder of the company, comments: „Allergic airway diseases have been steadily increasing over the last 60 years and treatment options are so far quite limited. Therefore, a safe and effective primary prophylaxis is a significant unmet medical need. Nowadays, every child in Europe and North America has a 20% risk of developing allergic airway disease and this risk increases up to 70% for children of allergic parents.”

Broad proof-of-concept has been established in relevant animal models and pre-clinical toxicity and safety testing has successfully been completed so that the project is prepared to enter the clinical Phase. “Having met this milestone we are looking forward to discuss the project with investors and established companies for partnering to expedite the clinical development”, states Marion Kauth.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protectimmun Teams Up with Johnson & Johnson Innovation and Imperial College
Company has entered into a research funding agreement with Janssen.
Tuesday, September 29, 2015
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Kitchen Utensils Can Spread Bacteria Between Foods
In a recent study researchers found that produce that contained bacteria would contaminate other produce items through the continued use of knives or graters—the bacteria would latch on to the utensils commonly found in consumers' homes and spread to the next item.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Safer, Faster Way To Remove Pollutants From Water
Using nanoparticles filled with enzymes proves more effective than current methods.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Novel Tumor Treatment
In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos has been published.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos